{"id":396843,"date":"2020-12-09T16:33:30","date_gmt":"2020-12-09T21:33:30","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=396843"},"modified":"2020-12-09T16:33:30","modified_gmt":"2020-12-09T21:33:30","slug":"stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases\/","title":{"rendered":"Stealth BioTherapeutics Announces Elamipretide Clinical Data to be Presented at the 13th International Conference on Cachexia, Sarcopenia and Wasting Diseases"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">BOSTON<\/span>, <span class=\"xn-chron\">Dec. 9, 2020<\/span> \/PRNewswire\/ &#8212;\u00a0Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that two abstracts have been selected for virtual presentations including a poster presentation and a late breaking research oral presentation at the upcoming 13<sup>th<\/sup> International Conference on Cachexia, Sarcopenia and Wasting Diseases being held online from <span class=\"xn-chron\">December 11-13, 2020<\/span>. The abstracts will feature encouraging findings from key elamipretide trials, including MMPOWER-3, highlighting improvements in the six minute walk test in genetic subgroups with mtDNA replisome disorders, and TAZPOWER, showing improvement in key biomarkers of mitochondrial dysfunction to potentially treat skeletal muscle wasting and cardiomyopathies. The presentations will be available to conference attendees via the conference website. <\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/969361\/Stealth_BioTherapeutics_Logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/969361\/Stealth_BioTherapeutics_Logo.jpg\" title=\"Stealth BioTherapeutics Logo (PRNewsFoto\/Stealth BioTherapeutics) (PRNewsfoto\/Stealth BioTherapeutics)\" alt=\"Stealth BioTherapeutics Logo (PRNewsFoto\/Stealth BioTherapeutics) (PRNewsfoto\/Stealth BioTherapeutics)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\n        <b>Details for the presentations are as follows:<\/b>\n      <\/p>\n<p>\n        <b>Title<\/b>: MMPOWER-3 Phase 3 Clinical Trial Results: Elamipretide improved six-minute walk test in individuals with mtDNA replisome disorders<br \/><b>Presenter<\/b>:\u00a0Michelangelo Mancuso, MD, PhD, University of <span class=\"xn-location\">Pisa<\/span><br \/><b>Session<\/b>: Late breaking research\/trials<br \/><b>Date and Time:<\/b>\u00a0Sunday, December 13<sup>th<\/sup>, <span class=\"xn-chron\">10:30-11:40 a.m. ET<\/span><\/p>\n<p>\n        <b>Title<\/b>: Changes in Plasma and Urinary Metabolites After Elamipretide in Barth Syndrome Patients: Analyses from the TAZPOWER Study<br \/><b>Presenter<\/b>:\u00a0Hilary Vernon, MD, PhD, <span class=\"xn-org\">Johns Hopkins University<\/span><br \/><b>Abstract #<\/b>: 8-02<br \/><b>Session<\/b>: 9.\u00a0Therapeutic development (clinical) + Therapeutic development (pre-clinical) I\u00a0<br \/><b>Date and Time:<\/b>\u00a0Saturday, December 12<sup>th<\/sup>, <span class=\"xn-chron\">1:55-2:45 p.m. ET<\/span><\/p>\n<p>\n        <b>About Stealth<\/b>\n      <\/p>\n<p>We are a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body&#8217;s main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases and are involved in many common age-related diseases, typically involving organ systems with high energy demands such as the heart, the eye, and the brain. We believe our lead product candidate, elamipretide, has the potential to treat both rare metabolic cardiomyopathies, such as Barth, Duchenne and Becker muscular dystrophies and Friedreich&#8217;s ataxia, rare mitochondrial diseases entailing nuclear DNA mutations, such as POLG-related disorders, as well as ophthalmic diseases entailing mitochondrial dysfunction, such as dry age-related macular degeneration and Leber&#8217;s hereditary optic neuropathy. We are evaluating our second-generation clinical stage candidate, SBT-272, for rare neurodegenerative disease indications following promising preclinical data in amyotrophic lateral sclerosis, or ALS. We have optimized our discovery platform to identify novel mitochondria-targeted compounds, including SBT-259, the SBT-550 series of compounds, and other compounds which may be nominated as therapeutic product candidates or utilized as scaffolds to deliver other compounds to mitochondria.<\/p>\n<p>\n        <b>Forward-Looking Statements <\/b>\n      <\/p>\n<p>This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking include statements about\u00a0the anticipated completion\u00a0of the registered direct offering. Statements that are not historical facts, including statements about\u00a0Stealth BioTherapeutics&#8217;\u00a0beliefs, plans and expectations, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;hope,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;possible,&#8221; &#8220;will,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Stealth BioTherapeutics may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements as a result of known and unknown risks, uncertainties and other important factors, including: Stealth BioTherapeutics&#8217; ability to obtain additional funding and to continue as a going concern; the impact of the COVID-19 pandemic; the ability to successfully demonstrate the efficacy and safety of\u00a0Stealth BioTherapeutics&#8217;\u00a0product candidates and future product candidates; the preclinical and clinical results for\u00a0Stealth BioTherapeutics&#8217;\u00a0product candidates, which may not support further development and marketing approval; the potential advantages of\u00a0Stealth BioTherapeutics&#8217;\u00a0product candidates; the content and timing of decisions made by the\u00a0U.S.\u00a0FDA, the EMA or other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies, which may affect the initiation, timing and progress of preclinical studies and clinical trials of\u00a0Stealth BioTherapeutics\u00a0product candidates;\u00a0Stealth BioTherapeutics&#8217;\u00a0ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors;\u00a0Stealth BioTherapeutics&#8217;\u00a0ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; and general economic and market conditions. These and other risks are described in greater detail under the caption &#8220;Risk Factors&#8221;\u00a0included in the\u00a0Stealth BioTherapeutics&#8217;\u00a0most recent Annual Report on Form 20-F filed with the\u00a0SEC,\u00a0as well as in any future filings with the\u00a0SEC. Forward-looking statements represent management&#8217;s current expectations and are inherently uncertain. Except as required by law,\u00a0Stealth BioTherapeutics\u00a0does not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances.<\/p>\n<p>\n        <b>Investor Relations<br \/><\/b>Stern Investor Relations<br \/><span class=\"xn-person\">Janhavi Mohite<\/span>, 212-362-1200<br \/><a target=\"_blank\" href=\"mailto:IR@StealthBT.com\" rel=\"nofollow noopener noreferrer\">IR@StealthBT.com<\/a>\u00a0<\/p>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE18924&amp;sd=2020-12-09\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases-301189822.html\">http:\/\/www.prnewswire.com\/news-releases\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases-301189822.html<\/a><\/p>\n<p>SOURCE  Stealth BioTherapeutics Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NE18924&amp;Transmission_Id=202012091630PR_NEWS_USPR_____NE18924&amp;DateId=20201209\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire BOSTON, Dec. 9, 2020 \/PRNewswire\/ &#8212;\u00a0Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that two abstracts have been selected for virtual presentations including a poster presentation and a late breaking research oral presentation at the upcoming 13th International Conference on Cachexia, Sarcopenia and Wasting Diseases being held online from December 11-13, 2020. The abstracts will feature encouraging findings from key elamipretide trials, including MMPOWER-3, highlighting improvements in the six minute walk test in genetic subgroups with mtDNA replisome disorders, and TAZPOWER, showing improvement in key biomarkers of mitochondrial dysfunction to potentially treat skeletal muscle wasting and cardiomyopathies. The presentations will &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Stealth BioTherapeutics Announces Elamipretide Clinical Data to be Presented at the 13th International Conference on Cachexia, Sarcopenia and Wasting Diseases&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-396843","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Stealth BioTherapeutics Announces Elamipretide Clinical Data to be Presented at the 13th International Conference on Cachexia, Sarcopenia and Wasting Diseases - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Stealth BioTherapeutics Announces Elamipretide Clinical Data to be Presented at the 13th International Conference on Cachexia, Sarcopenia and Wasting Diseases - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire BOSTON, Dec. 9, 2020 \/PRNewswire\/ &#8212;\u00a0Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that two abstracts have been selected for virtual presentations including a poster presentation and a late breaking research oral presentation at the upcoming 13th International Conference on Cachexia, Sarcopenia and Wasting Diseases being held online from December 11-13, 2020. The abstracts will feature encouraging findings from key elamipretide trials, including MMPOWER-3, highlighting improvements in the six minute walk test in genetic subgroups with mtDNA replisome disorders, and TAZPOWER, showing improvement in key biomarkers of mitochondrial dysfunction to potentially treat skeletal muscle wasting and cardiomyopathies. The presentations will &hellip; Continue reading &quot;Stealth BioTherapeutics Announces Elamipretide Clinical Data to be Presented at the 13th International Conference on Cachexia, Sarcopenia and Wasting Diseases&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-09T21:33:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/969361\/Stealth_BioTherapeutics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Stealth BioTherapeutics Announces Elamipretide Clinical Data to be Presented at the 13th International Conference on Cachexia, Sarcopenia and Wasting Diseases\",\"datePublished\":\"2020-12-09T21:33:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases\\\/\"},\"wordCount\":855,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/969361\\\/Stealth_BioTherapeutics_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases\\\/\",\"name\":\"Stealth BioTherapeutics Announces Elamipretide Clinical Data to be Presented at the 13th International Conference on Cachexia, Sarcopenia and Wasting Diseases - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/969361\\\/Stealth_BioTherapeutics_Logo.jpg\",\"datePublished\":\"2020-12-09T21:33:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/969361\\\/Stealth_BioTherapeutics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/969361\\\/Stealth_BioTherapeutics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Stealth BioTherapeutics Announces Elamipretide Clinical Data to be Presented at the 13th International Conference on Cachexia, Sarcopenia and Wasting Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Stealth BioTherapeutics Announces Elamipretide Clinical Data to be Presented at the 13th International Conference on Cachexia, Sarcopenia and Wasting Diseases - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases\/","og_locale":"en_US","og_type":"article","og_title":"Stealth BioTherapeutics Announces Elamipretide Clinical Data to be Presented at the 13th International Conference on Cachexia, Sarcopenia and Wasting Diseases - Market Newsdesk","og_description":"PR Newswire BOSTON, Dec. 9, 2020 \/PRNewswire\/ &#8212;\u00a0Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that two abstracts have been selected for virtual presentations including a poster presentation and a late breaking research oral presentation at the upcoming 13th International Conference on Cachexia, Sarcopenia and Wasting Diseases being held online from December 11-13, 2020. The abstracts will feature encouraging findings from key elamipretide trials, including MMPOWER-3, highlighting improvements in the six minute walk test in genetic subgroups with mtDNA replisome disorders, and TAZPOWER, showing improvement in key biomarkers of mitochondrial dysfunction to potentially treat skeletal muscle wasting and cardiomyopathies. The presentations will &hellip; Continue reading \"Stealth BioTherapeutics Announces Elamipretide Clinical Data to be Presented at the 13th International Conference on Cachexia, Sarcopenia and Wasting Diseases\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-09T21:33:30+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/969361\/Stealth_BioTherapeutics_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Stealth BioTherapeutics Announces Elamipretide Clinical Data to be Presented at the 13th International Conference on Cachexia, Sarcopenia and Wasting Diseases","datePublished":"2020-12-09T21:33:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases\/"},"wordCount":855,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/969361\/Stealth_BioTherapeutics_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases\/","name":"Stealth BioTherapeutics Announces Elamipretide Clinical Data to be Presented at the 13th International Conference on Cachexia, Sarcopenia and Wasting Diseases - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/969361\/Stealth_BioTherapeutics_Logo.jpg","datePublished":"2020-12-09T21:33:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/969361\/Stealth_BioTherapeutics_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/969361\/Stealth_BioTherapeutics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Stealth BioTherapeutics Announces Elamipretide Clinical Data to be Presented at the 13th International Conference on Cachexia, Sarcopenia and Wasting Diseases"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/396843","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=396843"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/396843\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=396843"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=396843"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=396843"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}